Skip to main content
. Author manuscript; available in PMC: 2020 Aug 29.
Published in final edited form as: J Thorac Oncol. 2018 Nov;13(11):1733–1742. doi: 10.1016/j.jtho.2018.05.004

Table 3.

Summary of Overall Survival Endpoints

Cohort 1 Cohort 2 Cohort 3
All
n = 31		 TC3 or IC3
n = 7		 All
n = 93		 TC3 or IC3
n = 38		 All
n = 13		 TC3 or IC3
n = 8
Median OS
Months (95% CI) 14.4 (12.8–22.1) 15.8 (13.0–32.3) 9.3 (5.8–17.6) 22.2 (5.8–NE) 6.8 (3.2–19.5) 7.0 (2.5–16.2)
12-month OS rate
% (95% CI) 74 (58–89) 86 (60–100) 43 (32–53) 55 (39–71) 38 (12–65) 38 (4–71)
30-month OS rate
% (95% CI) 25 (9–40) 29 (0–62) 25 (15–34) 43 (26–59) 19 (0–42) 19 (0–50)

CI, confidence interval; IC, immune cell; NE, not estimable; OS, overall survival; TC, tumor cell.